NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence

CONCLUSIONS: The GSLA10 signature outperformed the Oncotype DX signature in discerning tumours with unfavourable outcomes, previously categorised as luminal A by Prediction Analysis of Microarray 50 (PAM50) across three independent human cohorts. This new signature holds promise for identifying luminal A tumour patients with adverse prognosis, aiding in the development of personalised treatment strategies to significantly improve patient outcomes.PMID:38344872 | PMC:PMC10859882 | DOI:10.1002/ctm2.1554

Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Marina Mendiburu-Eli çabe Natalia Garc ía-Sancha Roberto Corchado-Cobos Ang élica Martínez-López Hang Chang Jian Hua Mao Adri án Blanco-Gómez Ana Garc ía-Casas Andr és Castellanos-Martín N élida Salvador Alejandro Jim énez-Navas Manuel Jes ús Source Type: research